Cardiol Therapeutics Inc.
NASDAQ:CRDLDrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $114.64M
- Beta
- 0.80
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.31M
Average 0.68M
CRDL Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Cardiol Therapeutics Inc.NASDAQ: CRDL
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns positive
Q1 FY2026 financing cash flow was CA$13.63M, compared with -CA$13.84K a year earlier. Trailing-twelve-month financing cash flow was CA$29.19M.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near CA$13.63M or moves back toward the trailing-twelve-month quarterly average of CA$7.3M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
CAD · from the cash flow
- Latest · FY2025
- 15.54M CAD
- Year-over-year change
- -17.5%
- 4-year CAGR
- -36.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.54M | -17.5% |
| FY2024 | 2024-12-31 | 18.84M | +34122.6% |
| FY2023 | 2023-12-31 | (55.38K) | -2.7% |
| FY2022 | 2022-12-31 | (53.93K) | -100.1% |
| FY2021 | 2021-12-31 | 93.44M | — |
Financing Cash Flow vs competitors
How CRDL compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +55.7% is the 5th highest of 8, against a peer median of +75.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IMAImageneBio Inc | LTM Mar 2026 | $132.22M USD | — | +398.3% | — |
| LTM Mar 2026 | $58.43M USD | +75.2% | +171.2% | 55651.4% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $52.42M USD | — | +132.0% | — |
| LTM Mar 2026 | $36.41M USD | +456.2% | +1477.9% | 237.5% | |
| LTM Jun 2025 | ₪34.85M ILS | -28.6% | — | 14.3% | |
| LTM Mar 2026 | $33.16M USD | +538.4% | -28.4% | — | |
| LTM Mar 2026 | CA$29.19M CAD | +55.7% | — | — | |
| LTM Mar 2026 | €6.23M EUR | -77.3% | +154.7% | 21245.3% | |
| FY2025 | $1.09M USD | +381.5% | — | 1707.8% | |
| LTM Mar 2026 | $267K USD | +4.7% | -71.1% | 0.3% | |
| Peer median (excluding CRDL) | — | +75.2% | +154.7% | 972.7% | |
Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.64M) | (30.93M) | (28.13M) | (36.68M) | (33.82M) |
| Depreciation & Amortization | 220.42K | 219.91K | 248.36K | 373.11K | 101.98K |
| Deferred Income Tax | (4.92M) | (9.16M) | 0 | 0 | 0 |
| Stock-Based Compensation | 8.5M | 5.01M | 4.16M | 14.28M | 10.7M |
| Change in Working Capital | 76.52K | 5.75M | (545.88K) | (931.57K) | (733.34K) |
| Accounts Receivables | (59.95K) | (144.18K) | 200.33K | (81.75K) | 135.43K |
| Inventory | 17.97K | (4.47M) | 0 | 0 | 0 |
| Accounts Payables | 2.39M | 4.47M | 0 | 0 | 0 |
| Other Working Capital | (2.27M) | 5.89M | (746.2K) | (849.82K) | (868.76K) |
| Other Non-Cash Items | 4.21M | 1.89M | (911.39K) | (2.1M) | (105.34K) |
| Operating Cash Flow | (23.55M) | (27.22M) | (25.18M) | (25.06M) | (23.85M) |
| Capital Expenditures | (12.92K) | (74.71K) | (64.31K) | (21.29K) | (24.48K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (12.92K) | (74.71K) | (64.31K) | (21.29K) | (24.48K) |
| Debt Repayment | (51.92K) | (53.93K) | (55.38K) | (41.53K) | (55.38K) |
| Common Stock Issued | 84.08M | 0 | 0 | 21.36M | 16.07M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.41M | (0) | 0 | (2.47M) | (477.03K) |
| Financing Cash Flow | 93.44M | (53.93K) | (55.38K) | 18.84M | 15.54M |
| Effect of Forex Changes | (11.13K) | 2.92M | 762.04K | 1.89M | (824.04K) |
| Net Change in Cash | 69.87M | (24.43M) | (24.54M) | (4.35M) | (9.16M) |
| Free Cash Flow | (23.56M) | (27.3M) | (25.24M) | (25.08M) | (23.88M) |
Cardiol Therapeutics Inc.
NASDAQ:CRDL
Intrinsic Alpha fair value
Locked
Current Price
$0.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.